Overview
| Trade Names: | Apo-Trifluoperazine; Eskazine; Eskazinyl; Fluoperazine; Jatroneural; Modalina; Novo-Trifluzine; PMS Trifluoperazine; Stelazine; Stelazine Concentrate; Stellazine; Synklor; Terfluzine; Trazine; Trifluoperazin; Trifluoperazina; Trifluoperazine Dihydrochloride; Trifluoperazine HCl; Trifluoperazine Hydrochloride; Trifluoromethylperazine; Trifluoroperazine; Trifluoroperazine Dihydrochloride; Trifluoroperazine Hydrochloride; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Triphtazin; Triphtazine; Triphthasine; Triphthazine; Triphthazine Dihydrochloride; Tryptazine; Tryptazine Dihydrochloride |
|---|---|
| Brand Mixtures: | Stelabid Forte (Isopropamide Iodide + Trifluoperazine Hydrochloride); Stelabid No 1 (Isopropamide Iodide + Trifluoperazine Hydrochloride); Stelabid No 2 (Isopropamide Iodide + Trifluoperazine Hydrochloride) |
| PharmGKB Accession Id: | PA451771 |
Description
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. PubChem (source: Drug Bank)
Indication
For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation. (source: Drug Bank)
ATC Therapeutic Category
- N05AB:Phenothiazines with piperazine structure
Pharmacology, Interactions, and Contraindications
Mechanism Of Action
Trifluoperazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. (source: Drug Bank)
Pharmacology
Trifluoperazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Trifluoperazine has not been shown effective in the management of behaviorial complications in patients with mental retardation. (source: Drug Bank)
Absorption, Distribution, Metabolism, Elimination & Toxicity
Toxicity
Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness. (source: Drug Bank)
Isomeric SMILES Code:
CN1CCN(CC1)CCCN2c3ccccc3Sc4c2cc(cc4)C(F)(F)F (source: Drug Bank)
A list of non-curated publications that mention this drug along with other genes is available.
Drug Targets
| Gene | Description | |
|---|---|---|
| ATP4A |
|
(source: Drug Bank) |
| ADRA1A |
|
(source: Drug Bank) |
| CALY |
|
(source: Drug Bank) |
| DRD2 |
|
(source: Drug Bank) |
A list of non-curated publications that mention this drug along with other drugs is available.
Drug Interactions
| Drug | Description | |
|---|---|---|
| amphetamine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| benzphetamine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| bromocriptine |
|
The phenothiazine decreases the effect of bromocriptine (source: Drug Bank) |
| cisapride |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| dexfenfluramine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| dextroamphetamine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| diethylpropion |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| donepezil |
|
Possible antagonism of action (source: Drug Bank) |
| fenfluramine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| galantamine |
|
Possible antagonism of action (source: Drug Bank) |
| gatifloxacin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| grepafloxacin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| guanethidine |
|
The agent decreases the effect of guanethidine (source: Drug Bank) |
| levofloxacin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| mazindol |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| methamphetamine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| metrizamide |
|
Increased risk of convulsions (source: Drug Bank) |
| phendimetrazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| phenmetrazine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| phentermine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| phenylpropanolamine |
|
Decreased anorexic effect, may increase psychotic symptoms (source: Drug Bank) |
| rivastigmine |
|
Possible antagonism of action (source: Drug Bank) |
| sparfloxacin |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
| terfenadine |
|
Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank) |
Curated Information
The following diseases are in curated knowledge about this drug.
| Disease | Relationship | Evidence | |
|---|---|---|---|
|
Parkinson Disease |
|
Publications |
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Additional Datasets
These datasets are minimally curated and are sorted alphabetically by title.
LinkOuts
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.